• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Third party research

Bittium: Q1 missed, but order intake momentum remains exceptional - NuWays AG Research

Bittium

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Yesterday, Bittium published its Q1'26 business review. Group sales increased 10.2% yoy to € 21.3m vs. eNuW € 26.9m and BBG cons. € 27.6m, with the miss mainly stemming from deliveries timing, thus not a cause for concern (eNuW). EBITDA came in at € 2.8m vs. eNuW € 5.2m and BBG cons. € 6.4m, while EBIT of € 1.5m was in line with eNuW but below BBG cons. € 2.9m. As guided in February, sales and operating profit are expected to be heavily H2-weighted, reflecting the typical seasonality of the business.

We keep our BUY rating and € 40 PT unchanged, based on DCF.